The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis.
about
The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/OmiWilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyAPOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcriptsRe-adapting T cells for cancer therapy: from mouse models to clinical trials.Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes.Characterization of the transcriptome profiles related to globin gene switching during in vitro erythroid maturation.Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemiasPrognostic relevance of Wilms tumor 1 (WT1) gene Exon 7 mutations in-patient with cytogenetically normal acute myeloid leukemiaWT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell lineAssociation between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese populationThe Wilms' tumour suppressor protein WT1 acts as a key transcriptional repressor of the human thromboxane A2 receptor gene in megakaryocytes.Down-regulatory mechanism of mammea E/BB from Mammea siamensis seed extract on Wilms' Tumor 1 expression in K562 cellsThe transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xLEnhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities.The biological basis for immunotherapy in patients with chronic myelogenous leukemia.Homology modeling and molecular dynamics studies of Wilms' tumor gene 1 frameshift mutations in exon 7.Wilms' Tumour gene 1 (WT1) as an immunotherapeutic targetThe podocyte as a target: cyclosporin A in the management of the nephrotic syndrome caused by WT1 mutations.Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes.Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.Biological therapy and the immune system in patients with chronic myeloid leukemia.MicroRNAs: potential regulators of renal development genes that contribute to CAKUT.Malformation syndromes associated with disorders of sex development.A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.Pharmacogenomics and the treatment of acute myeloid leukemia.The Role of WT1 in Embryonic Development and Normal Organ Homeostasis.Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients.Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways.HtrA2, taming the oncogenic activities of WT1.Wilms tumor 1 gene mutations in patients with cytogenetically normal acute myeloid leukemia.Changes in expression of WT1 during induced differentiation of the acute myeloid leukemia cell lines by treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid.Preferentially Expressed Antigen of Melanoma (PRAME) and Wilms' Tumor 1 (WT 1) Genes Expression in Childhood Acute Lymphoblastic Leukemia, Prognostic Role and Correlation with Survival.WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group.Wilms' tumor 1 gene modulates Fas-related death signals and anti-apoptotic functions in hepatocellular carcinoma.The clinical characteristics and prognostic significance of AID, miR-181b, and miR-155 expression in adult patients with de novo B-cell acute lymphoblastic leukemia.Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences.
P2860
Q24655084-8485327C-7F44-4E1F-8A0C-D5A34B938740Q27851436-0B0E04CC-D01E-461D-93A2-06B7FCA90911Q28259425-42FF6750-D548-45BD-8162-905850260FB3Q33588711-947627AD-0B82-453D-90A6-229BFDB0B4A6Q33886181-AC25790E-8216-47EA-9B10-51E04E4E6B36Q33992114-0049B9F0-F5DA-42F9-8A78-41C19A312D07Q34001125-678C1CFD-DBA0-46E1-9836-E49A87E9FFAAQ34248320-AE1B2AAD-2DAB-4D2E-B3DB-DAB10626C518Q34374079-E48A63B0-E5AF-49BC-9FB1-886738407641Q34569014-F8AA3C9E-F040-45B5-AE08-60F0B632C905Q34710425-B53C1E30-AF12-4490-9010-00E48C12A636Q35666497-E681260B-D010-449C-B08C-A1D5464C18A7Q35889126-42E8CB23-A20E-4674-8B15-6A0A0BC924F8Q36021773-081A0B5F-C0EE-4936-8DBF-E897DE44009AQ36294675-BA69EF47-EEAA-451F-92AE-426B2862DE60Q37026759-27B2161F-FD6C-4968-99AE-D8C5B5B5F4A6Q37193866-F8E90D13-31DB-4B9C-A80A-8C7DD4894167Q37428671-38A4F468-5A49-4DAF-9AA1-A6E0736224CBQ37567685-A1E4B032-0AFD-40C4-A957-44B0A75E8D9CQ37704104-C6E8DC65-7AE5-44B6-81F2-6E9DC503419BQ37836591-F8E20974-173C-4A46-9F7B-D09FEF66F07EQ37872296-85D71C7C-90D3-4B41-8EE0-476D64EC5B69Q37954583-72344375-14AC-460F-A392-BBFE8B2C3CAFQ38015742-C3D2D91B-020A-4837-97D9-B63010A2816AQ38133419-6F0F7C21-819F-4F4F-A6C0-4E52E60263C7Q38218950-271BAA50-4614-4E13-91C3-122B6D265757Q38661750-31D099D4-9C7B-4081-8D4F-41977EA8E9A6Q38887034-830BFF12-BD5D-4982-8EA3-4C1392BF966DQ38897318-B3CC30F5-0969-4374-A57D-FE29B58088FBQ39273693-AF0E0735-D60F-4BEB-A428-C4CEE9B9D30DQ39631733-7DE14B0A-8D2E-45CF-A1B4-D52BC0516060Q39655836-99F9E8FE-C652-43B3-A7F5-9A896C65DEE1Q42061130-0B14069E-93AE-4616-9D65-5F8114086B8DQ42191008-3C333A0E-F9C6-4A66-BC75-A9EC322136EFQ42538957-40597FA6-5CDD-4284-934B-B5DEF21498AFQ42767013-E953419F-4B21-4CF9-B4F3-E0E10ED7E242Q44097808-E8450E2C-BF52-4F7C-9DFE-B6C6A7A56538Q44584782-1DC3DB46-A9AD-4F1E-9C5A-3305CFB7605FQ53537247-EE7B177E-E0D2-4B58-A919-641B4F634C2AQ54318403-BD7B940D-4ED1-4E31-9DF3-14147E0082DE
P2860
The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis.
@en
type
label
The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis.
@en
prefLabel
The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis.
@en
P2860
P1476
The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis.
@en
P2093
David M Loeb
Suzie Ariyaratana
P2860
P356
10.1017/S1462399407000336
P577
2007-05-24T00:00:00Z